Tag:

Puma Biotechnology

Latest Headlines

Latest Headlines

Puma tanks on a fresh setback for its breast cancer drug

Puma Biotechnologies is walking back some bullish prognostications for its breast cancer treatment, delaying its planned FDA submission by as much as a year and lending weight to some creeping doubts about its top prospect.

Puma shrugs off an 'expected' Phase II failure for its breast cancer drug

Puma Biotechnology's closely watched neratinib failed to beat out the blockbuster Herceptin in a mid-stage breast cancer trial, a miss the company said was no surprise as it touted success on a secondary goal.

Puma shares triple on positive PhIII neratinib data, plans to file for approval

Shares of Puma Biotechnology soared more than 220% after the markets closed on Tuesday as investors cheered the biotech's positive Phase III numbers for a late-stage study of their lead drug neratinib (PB272). 

ASCO spotlight burns Puma shares

Puma Biotechnology's stock plunged 25% on Monday after investors soured on its "positive" news about neratinib, or PB272, with only three of 40 breast cancer patients in a study demonstrating a partial response.

Puma surges as neratinib beats Herceptin in head-to-head breast cancer study

Puma Biotechnology is boasting that its experimental cancer drug neratinib bested Herceptin in a head-to-head study of HER2-positive breast cancer when used ahead of surgery.

I-SPY a controversy over Puma's positive PhII test of neratinib

The brouhaha that erupted on Twitter when Puma Biotechnology switched to a Bayesian statistical model in its I-SPY 2 study to predict the likelihood of late-stage success of neratinib for metastatic HER2-positive breast cancer indicates that this approach could make the industry pause before the Bayesian predictive formula is widely adopted in the biotech world. 

Karyopharm snags $19M more to expand work on anticancer contender

Karyopharm has scored an additional $19 million for its Series B round of financing, padding the $48.2 million raised for the round in May, for a total of more than $67 million, among the largest this year for a drug developer.

Puma Biotech shares roaring up amid M&A meow

The cancer drug developer's shares have risen more than 50% in 2013 as the company begins late-stage development of its lead drug neratinib for patients with metastatic HER2-positive breast cancer.

Puma's Auerbach revs up PhIII plans after snagging SPA on cancer drug

Puma Biotechnology, which is swiftly moving its experimental cancer drug PB272 (neratinib) into a pivotal Phase III program, has now reached agreement with the FDA on a special protocol assessment, pushing a combo approach of the experimental treatment with Xeloda into a head-to-head showdown with Tykerb plus Xeloda for treatment-resistant, HER2 positive breast cancer.

Venture firm preps $100M fund for late-stage life sciences investments

Following a well-defined trail of venture groups into late-stage investing, San Francisco-based Foresite Capital Management says it has wrapped a $100 million fund that will be heavily focused on the most disruptive and most promising late-stage technology it can find in biotech, genomics and diagnostics, among other healthcare fields.